Curis (NASDAQ:CRIS) Shares Scheduled to Reverse Split on Monday, July 6th

Curis, Inc. (NASDAQ:CRIS) shares are set to reverse split on the morning of Monday, July 6th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, July 5th.

Curis Stock Performance

CRIS stock traded down $0.08 during mid-day trading on Thursday, reaching $0.35. The company had a trading volume of 2,359,126 shares, compared to its average volume of 8,975,921. The company has a market capitalization of $13.51 million, a price-to-earnings ratio of -0.29 and a beta of 3.08. The firm has a fifty day simple moving average of $0.49 and a 200 day simple moving average of $0.75. Curis has a fifty-two week low of $0.18 and a fifty-two week high of $2.01.

Curis (NASDAQ:CRIS) last announced its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.92). As a group, analysts predict that Curis will post -1.27 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have commented on CRIS. Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a report on Monday, April 20th. Zacks Research lowered shares of Curis from a “hold” rating to a “strong sell” rating in a report on Friday, May 22nd. Wall Street Zen raised shares of Curis to a “hold” rating in a research report on Saturday, March 28th. Finally, HC Wainwright reiterated a “buy” rating and set a $17.00 target price on shares of Curis in a research note on Friday, March 20th. One equities research analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $17.00.

Institutional Investors Weigh In On Curis

Institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC increased its stake in Curis by 37.3% in the fourth quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock valued at $238,000 after purchasing an additional 65,404 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of Curis by 2,883,237.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock worth $228,000 after buying an additional 230,659 shares during the last quarter. Armistice Capital LLC boosted its holdings in shares of Curis by 8.7% in the 3rd quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock valued at $1,624,000 after buying an additional 78,265 shares in the last quarter. Squarepoint Ops LLC boosted its holdings in shares of Curis by 17.9% in the 3rd quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 8,973 shares in the last quarter. Finally, Maverick Capital Ltd. grew its position in shares of Curis by 7.8% in the 2nd quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock valued at $1,472,000 after buying an additional 49,554 shares during the last quarter. Hedge funds and other institutional investors own 29.97% of the company’s stock.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.